e-Drug3D

1950

TENAPANOR

INN
TENAPANOR

cas 1234423-95-0

CLASS

NERVOUS SYSTEM
SODIUM/HYDROGEN EXCHANGER 3 (NHE3) INHIBITOR
TREATMENT OF IRRITABLE BOWEL SYNDROME WITH CONSTIPATION (IBS-C)

ROUTE (list)

ORAL

ATC code

A06AX08

PK parameters

PPB 99 PERCENT

Solubility

PRACTICALLY INSOLUBLE IN WATER

Target

TARGET SODIUM/HYDROGEN EXCHANGER 3 (NHE3)

DrugCentral

Sodium,hydrogen exchanger 3 UNIPROT P48764 SLC9A3

Download SDF file

12,15-Dioxa-2,7,9-triazaheptadecanamide,17-[[[3-[(4S)-6,8-dichloro-1,2,3,4-tetrahydro-2-methyl-4-isoquinolinyl]phenyl]sulfonyl]amino]-N-[2-[2-[2-[[[3-[(4S)-6,8-dichloro-1,2,3,4-tetrahydro-2-methyl-4-isoquinolinyl]phenyl]sulfonyl]amino]ethoxy]ethoxy]ethyl]-8-oxo-

Formula:
C50H66Cl4N8O10S2

Calculated chemical properties:

MW 1145.05
NB_atoms 74
XLogP 6.16
PSA 233.488
NB_HD 6
NB_HA 18
fsp3 0.48
Lipinski(0=no;1=yes) 0

FDA
NDA 211801 (pdf not found) INN (TENAPANOR HYDROCHLORIDE) IBSRELA (ARDELYX INC) APPROVAL= AP YEAR= 2019 NEWMOLECULARENTITY
NDA 213931 (pdf not found) INN (TENAPANOR HYDROCHLORIDE) XPHOZAH (ARDELYX INC) APPROVAL= AP YEAR= 2023 NEWAPPLICATION